ONCE Spark Therapeutics Inc.

113.57
0  0%
Previous Close 113.57
Open
Price To Book 12.65
Market Cap 4,375,090,500
Shares 38,523,294
Volume 0
Short Ratio
Av. Daily Volume 269,807
Stock charts supplied by TradingView

NewsSee all news

  1. Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy

    Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE)

  2. Roche purchases shares in tender offer for Spark Therapeutics, Inc.

    Roche intends to complete Spark acquisition today Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche's wholly owned subsidiary

  3. Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc

      All antitrust approvals required to close the transaction received. Basel, 16 December 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the

  4. Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

    Basel, 16 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the UK Competition and Markets Authority has unconditionally cleared Roche's pending

  5. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019

    Basel, 9 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial commenced early 2019.
SPK-8011
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
SPK-9001
Hemophilia B
Phase 1/2 ongoing.
SPK-7001 (SPK-CHM)
Choroideremia
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies

Latest News

  1. Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy

    Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE)

  2. Roche purchases shares in tender offer for Spark Therapeutics, Inc.

    Roche intends to complete Spark acquisition today Basel, 17 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche's wholly owned subsidiary

  3. Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc

      All antitrust approvals required to close the transaction received. Basel, 16 December 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the

  4. Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

    Basel, 16 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that the UK Competition and Markets Authority has unconditionally cleared Roche's pending

  5. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019

    Basel, 9 December 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  6. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 22 November 2019 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  7. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  8. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  9. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  10. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 29 October 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  11. Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

    PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that

  12. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all

  13. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 30 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  14. Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

    Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD Spark Therapeutics unveils enhanced ID YOUR IRD® genetic test for

  15. Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

    Basel, 3 September 2019  - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and Spark Therapeutics, Inc. (NASDAQ:ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender offer to

  16. Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

    PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the